Association of Rac1 Expression with Trastuzumab Resistance In HER2-Positive Breast Cancer

Basit Öğe Kaydı
dc.contributor.authorVarol, Umut
dc.contributor.authorKaraca, Burcak
dc.contributor.authorPatir, Pusem
dc.contributor.authorSener, Alper
dc.contributor.authorZekioglu, Osman
dc.contributor.authorSanli, Ulus A.
dc.contributor.authorUslu, Ruchan
dc.date.accessioned2019-10-27T21:55:43Z
dc.date.available2019-10-27T21:55:43Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractSeveral molecular mechanisms are believed to take role in the development of trastuzumab resistance in breast cancer patients with overexpressing HER2. However, the sequence and the activity of these mechanisms are still unclear. In this study, Rac1 and neuregulin 1 (NRG1), two of ErbB pathway related proteins, were analyzed in HER2-positive breast cancer patients to investigate their roles in trastuzumab resistance. Trastuzumab resistance in metastatic breast cancer treatment was defined as a progression within six months of the treatment and in the adjuvant manner as an occurrence of local/distant recurrence before completion of treatment. Expression of Rac1 and NRG1 by immunohistochemistry (IHC) was studied in all 22 (n=12 adjuvant, n=10 metastatic) trastuzumab-resistant and 27 control tissue samples. The staining intensity of Rac1 was statistically significant in adjuvant treatment resistant group when compared with the controls (p=0.02). In addition, when all resistant groups were compared with the control groups, Rac1 staining intensity was denser (p=0.051). NRG1 staining intensity was in tendency to be denser as compared to control group, however it did not reach to a statistically significant level (p=0.09). In HER2-positive breast cancer, presence of Rac1 protein is significantly associated with early response failure to adjuvant trastuzumab therapy. However, further studies with larger groups are warranted to show the value of these molecules in predicting the response to trastuzumab-based therapies.en_US
dc.identifier.doi10.4999/uhod.12062
dc.identifier.endpage226en_US
dc.identifier.issn1306-133X
dc.identifier.issn1306-133Xen_US
dc.identifier.issue4en_US
dc.identifier.startpage219en_US
dc.identifier.urihttps://doi.org/10.4999/uhod.12062
dc.identifier.urihttps://hdl.handle.net/11454/48264
dc.identifier.volume23en_US
dc.identifier.wosWOS:000329334500002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAkad Doktorlar Yayinevien_US
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast Canceren_US
dc.subjectNeuregulin 1en_US
dc.subjectRac1en_US
dc.subjectTrastuzumab resistanceen_US
dc.titleAssociation of Rac1 Expression with Trastuzumab Resistance In HER2-Positive Breast Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu